Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: A randomized, placebo-controlled trial in China

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 1, 2014, Pages 2687-2694

  Li, Rong Cheng ^a   Huang, Teng ^a   Li, Yanping ^a   Luo, Dong ^b   Tao, Junhui ^c   Fu, Botao ^d   Si, Guoai ^e   Nong, Yi ^a   Mo, Zhaojun ^a   Liao, XueYan ^f   Luan, Ivy ^f   Tang, Haiwen ^f   Rathi, Niraj ^g   Karkada, Naveen ^g   Han, Htay Htay ^h  

^a GuangXi Center for Disease Prevention and Control   (China)

^b Liucheng County Center for Disease Prevention and Control   (China)

^c Liujiang County Center for Disease Prevention and Control   (China)

^d Luzhai County Center for Disease Prevention and Control   (China)

^e Jinchengjiang Region Center for Disease Prevention and Control   (China)

^f GLAXOSMITHKLINE   (China)

^g GlaxoSmithKline Pharmaceuticals Ltd   (India)

^h GLAXOSMITHKLINE   (United States)

Author keywords

China; Efficacy; Guangxi Province; RIX4414; Rotavirus gastroenteritis; Safety

Indexed keywords

PLACEBO; ROTACLONE; ROTAVIN M1; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASPHYXIA; ATTITUDE TO HEALTH; BRAIN CONTUSION; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN HERNIA; BRONCHITIS; BRONCHOPNEUMONIA; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM INFECTION; CHINA; COHORT ANALYSIS; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CORTICAL DYSPLASIA; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWNING; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROENTERITIS; HISTIOCYTOSIS; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MENINGITIS; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NONHUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; SEASONAL VARIATION; SKULL FRACTURE; SUBARACHNOID HEMORRHAGE; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

EID: 84896723313     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26319     Document Type: Article

References (29)

1. Bernstein DI. Rotavirus overview. Pediatr Infect Dis J 2009; 28(Suppl):S50-3; http://dx.doi.org/10.1097/INF.0b013e3181967bee; PMID:19252423
2. Chandran A, Fitzwater S, Zhen A, Santosham M. Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. Biologics 2010; 4:213-29; PMID:20714358
3. O'Ryan M, Linhares AC. Update on Rotarix: an oral human rotavirus vaccine. Expert Rev Vaccines 2009; 8:1627-41; http://dx.doi.org/10.1586/erv.09. 136; PMID:19943758
4. World Health Organization. Rotavirus vaccines. Wkly Epidemiol 2007; 82:285-95
5. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200(Suppl 1):S9-15; http://dx.doi.org/10. 1086/605025; PMID:19817620
6. Fang Z-Y, Wang B, Kilgore PE, Bresee JS, Zhang L-J, Sun L-W, Du ZQ, Tang JY, Hou AC, Shen H, et al. Sentinel hospital surveillance for rotavirus diarrhea in the People's Republic of China, August 2001-July 2003. J Infect Dis 2005; 192(Suppl 1):S94-9; http://dx.doi.org/10.1086/431505; PMID:16088812
7. Liu N, Yen C, Fang Z-Y, Tate JE, Jiang B, Parashar UD, Zeng G, Duan ZJ. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. Vaccine 2012; 30:6940-5; http://dx.doi.org/10.1016/j.vaccine.2012.05.084; PMID:22705174
8. Nelson EAS, Bresee JS, Parashar UD, Widdowson MA, Glass RI; Asian Rotavirus Surveillance Network. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008; 26:3192-6; http://dx.doi.org/10.1016/j. vaccine.2008.03.073; PMID:18485546
9. Duan Z-J, Liu N, Yang S-H, Zhang J, Sun L-W, Tang J-Y, Jin Y, Du ZQ, Xu J, Wu QB, et al. Hospital-based surveillance of rotavirus diarrhea in the People's Republic of China, August 2003-July 2007. J Infect Dis 2009; 200(Suppl 1):S167-73; http://dx.doi.org/10.1086/605039; PMID:19817597
10. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, Jiang B, Gentsch JR. Rotavirus vaccines: current prospects and future challenges. Lancet 2006; 368:323-32; http://dx.doi.org/10.1016/S0140-6736(06) 68815-6; PMID:16860702
11. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; http://dx.doi.org/10.1056/NEJMoa052434; PMID:16394298
12. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al.; Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; http://dx.doi.org/10.1056/NEJMoa052664; PMID:16394299
13. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63; http://dx.doi.org/10.1016/S0140-6736(07)61744-9; PMID:18037080
14. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, et al.; Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9; http://dx.doi.org/10.1016/S0140-6736(08)60524- 3; PMID:18395579
15. Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine 2012; 30(Suppl 1):A44-51; http://dx.doi.org/10.1016/j.vaccine.2011.08.080; PMID:22520136
16. Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine 2012; 30(Suppl 1):A36-43; http://dx.doi.org/10.1016/j.vaccine.2011.09.120; PMID:22520135
17. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27:5936-41; http://dx.doi.org/10.1016/j.vaccine. 2009.07.098; PMID:19679216
18. Luan T, Trang NV, Phuong NM, Nguyen HT, Ngo HT, Nguyen HT, Tran HB, Dang HN, Dang AD, Gentsch JR, et al. Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. Vaccine 2009; 27(Suppl 5):F130-8; PMID:19931712; http://dx.doi.org/10.1016/j. vaccine.2009.08.086
19. Anh DD, Trang NV, Thiem VD, Anh NTH, Mao ND, Wang Y, et al. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine 2012; 30S:A114-21; http://dx.doi.org/10.1016/j.vaccine.2011.07.118
20. Fu C, He Q, Xu J, Xie H, Ding P, Hu W, Dong Z, Liu X, Wang M. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine 2012; 31:154-8; http://dx.doi.org/10.1016/j.vaccine. 2012.10.078; PMID:23127516
21. Wang X-Y, Riewpaiboon A, von Seidlein L, Chen X-B, Kilgore PE, Ma J-C, Qi SX, Zhang ZY, Hao ZY, Chen JC, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009; 49:1202-10; http://dx.doi.org/10.1086/605632; PMID:19739973
22. Ouyang Y, Ma H, Jin M, Wang X, Wang J, Xu L, Lin S, Shen Z, Chen Z, Qiu Z, et al. Etiology and epidemiology of viral diarrhea in children under the age of five hospitalized in Tianjin, China. Arch Virol 2012; 157:881-7; http://dx.doi.org/10.1007/s00705-012-1235-9; PMID:22318672
23. Lou J-T, Xu X-J, Wu Y-D, Tao R, Tong M-Q. Epidemiology and burden of rotavirus infection among children in Hangzhou, China. J Clin Virol 2011; 50:84-7; http://dx.doi.org/10.1016/j.jcv.2010.10.003; PMID:21041114
24. Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 2011; 29:6335-41; http://dx.doi.org/10.1016/j.vaccine.2011.05.017; PMID:21640780
25. De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R, Cheuvart B. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr Infect Dis J 2009; 28:261-6; http://dx.doi.org/10.1097/INF.0b013e3181907177; PMID:19289978
26. Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatr Infect Dis J 2009; 28:225-32; http://dx.doi.org/10.1097/ INF.0b013e31819715fa; PMID:19209095
27. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, Booy R, Bines JE; PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011; 29:3061-6; http://dx.doi.org/10.1016/j. vaccine.2011.01.088; PMID:21316503
28. Velázquez FR, Colindres RE, Grajales C, Hernández MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012; 31:736-44; http://dx.doi.org/10.1097/INF. 0b013e318253add3; PMID:22695189
29. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67; http://dx.doi.org/10.3109/00365549009027046; PMID:2371542